| CAPRICOR THERAPEUTICS |
| USA |
| Gesundheit |
| US14070B3096 / A2PLU4 |
| 4LN2 (Frankfurt) / CAPR (NASDAQ) |
| FRA:4LN2, ETR:4LN2, 4LN2:GR, NASDAQ:CAPR |
| - |
| https://capricor.com/ |
|
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company developing cell- and exosome-based therapies for rare diseases with significant unmet medical needs. Its leading program, deramiocel, is an allogeneic cardiac-derived cell therapy ..
>Volltext.. |
| 465.52 Mio. EUR |
| 335.89 Mio. EUR |
| - |
| -119.45 Mio. EUR |
| -116.17 Mio. EUR |
| -2.2 EUR |
| 81.73 Mio. EUR |
| 18.79 Mio. EUR |
| -93.35 Mio. EUR |
| 7.22 |
| -100% |
| -90.76% |
| - |
| - |
| - |
| - |
| CAPRICOR THERAPEUTICS, CAPRICOR THERAPEUTIC |
| 10.11.26 |